Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

Next Previous
Trial Profile

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Jun 2023 Results of secondary analysis (n=221) assessing the spontaneous clearance among patients with asymptomatic anal, pharyngeal, vaginal and urethral NG infections and the determinants associated with spontaneous clearance, participants from NABOGO trial, published in the Sexually Transmitted Infections.
  • 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for fosfomycin arm/group) has not been met as per results published in The Lancet Infectious Diseases
  • 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for Gentamicin arm/group) has not been met as per results published in The Lancet Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top